NewsBenzinga火箭一号旗下 Hoth Therapeutics 子公司计划在中期疗效数据公布后终止 HT-001 的 2a 期临床研究;拟寻求 FDA 对开展 HT-001 潜在 3 期临床项目的反馈 火箭一号旗下 Hoth Therapeutics 子公司计划在中期疗效数据公布后终止 HT-001 的 2a 期临床研究;拟寻求 FDA 对开展 HT-001 潜在 3 期临床项目的反馈 Benzinga 2026.11.03 13:20 (GMT+0) Open on Benzinga Other news Motorola Solutions Hikes Quarterly Dividend From $1.21 To $1.34 Per Share These 9 Congress Members Could Have Increased Interest in Nvidia’s Q3 Earnings as 2026 Shareholders $100 Invested In Cigna Group 20 Years Ago Would Be Worth This Much Today Needham Maintains Buy on FuboTV, Lowers Price Target to $10 BTIG Reiterates Buy on Amer Sports, Maintains $42 Price Target If You Invested $1000 In Ulta Beauty Stock 15 Years Ago, You Would Have This Much Today